Scinai Faces Going Concern Amidst Persistent Losses, Cash Dwindles

TL;DR

**SCNI is a high-risk bet; with only $1.6M cash and a going concern, they need a cash infusion ASAP or it's lights out.**

AI Summary

Scinai Immunotherapeutics Ltd. (SCNI) reported significant operating losses of $7.5 million in 2025, an improvement from $8.6 million in 2024 and $9.7 million in 2023. The company's cash and cash equivalents stood at $1.6 million as of December 31, 2025, down from $1.9 million in 2024, and up from $0.9 million in 2023. Negative cash flows from operating activities were $6.0 million in 2025, $6.3 million in 2024, and $9.3 million in 2023. Scinai has an accumulated deficit of $122.0 million as of December 31, 2025, and its financial statements include a going concern qualification, indicating substantial doubt about its ability to continue operations for at least one year. The company's strategy involves growing its CDMO business to generate revenue while advancing its early-stage NanoAbs therapeutic pipeline, which currently generates no revenue. Securing additional financing is critical for continued operations and growth, as current cash is insufficient to fund planned operations for the next 12 months.

Why It Matters

Scinai's precarious financial position, highlighted by a going concern qualification and an accumulated deficit of $122.0 million, signals high risk for investors. The company's ability to secure additional financing is paramount; failure could lead to significant dilution for existing shareholders or even cessation of operations. For employees and customers, the uncertainty surrounding Scinai's financial viability could impact job security and service continuity in its CDMO business. In the competitive biotech and CDMO landscape, Scinai's struggle to generate sufficient revenue from its CDMO activities to offset R&D costs puts it at a disadvantage against more established players.

Risk Assessment

Risk Level: high — Scinai's risk level is high due to a 'going concern' qualification in its financial statements and insufficient cash to fund operations for the next 12 months. As of December 31, 2025, the company had only $1.6 million in cash and cash equivalents, while incurring operating losses of $7.5 million and negative cash flows from operating activities of $6.0 million for the year.

Analyst Insight

Investors should avoid SCNI given the substantial doubt about its ability to continue as a going concern and its reliance on future financing. Current shareholders should monitor closely for any announcements regarding successful capital raises or significant cost reductions, as failure to secure funding could lead to further dilution or cessation of operations.

Key Numbers

• $1.6M — Cash and Cash Equivalents (as of December 31, 2025, down from $1.9M in 2024)
• $7.5M — Operating Losses (for the year ended December 31, 2025, an improvement from $8.6M in 2024)
• $6.0M — Negative Cash Flows from Operating Activities (for the year ended December 31, 2025, an improvement from $6.3M in 2024)
• $122.0M — Accumulated Deficit (as of December 31, 2025, indicating significant historical losses)
• 13,872,899,584 — Ordinary Shares Outstanding (as of December 31, 2025)
• 4,000 — Ordinary Shares per ADS (new ratio effective May 21, 2024)
• $0.46M — Working Capital (as of December 31, 2025, down from $0.59M in 2024)

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — Registrant
• Amir Reichman (person) — Chief Executive Officer
• Nasdaq Capital Market (regulator) — exchange where ADSs are registered
• SEC (regulator) — United States Securities and Exchange Commission
• MPG (company) — licensor for NanoAbs programs
• UMG (company) — licensor for NanoAbs programs
• Sanofi (company) — owner of Nanobody trademark

FAQ

Risk Factors

• Going Concern and Financing Needs [high — financial]: The company has a going concern qualification, indicating substantial doubt about its ability to continue operations. It requires significant additional financing to fund operations and development. Failure to secure capital may force delays, reductions, or termination of activities, potentially leading to cessation of operations. Any new financing could result in substantial dilution or restrictive covenants.
• History of Operating Losses and Profitability [high — financial]: Scinai has a history of operating losses and is not currently profitable. While the CDMO business generates revenue, the company may continue to incur losses and may not achieve profitability in the near future, or at all.
• Nasdaq Listing Requirements [medium — financial]: Failure to meet the continued listing requirements of Nasdaq could result in the delisting of the company's ADSs. This would adversely affect the market liquidity and price of its shares.
• CDMO Business Dependence on Market Demand [medium — operational]: The CDMO business is dependent on market demand for its services, the ability to attract and retain customers, enter into commercially acceptable contracts, and deliver high-quality services on time. Failure in these areas could negatively impact revenues and prospects.
• CDMO Regulatory and Quality Compliance [medium — regulatory]: CDMO operations are complex and subject to strict regulatory and quality requirements. Any failure to meet these requirements could harm the company's reputation and business.
• Dependence on Third Parties and Collaborators [medium — operational]: The company relies on third parties and collaborators for the development, commercialization, and marketing of its product candidates. There is a risk of not being successful in entering into or maintaining these relationships.
• Early-Stage Therapeutic Pipeline Risk [high — operational]: The company's product candidates are at an early stage of development and currently generate no revenue. There is a significant risk that the company may not be successful in discovering, developing, or commercializing any of these product candidates.
• Clinical Trial Uncertainty [high — operational]: Clinical trials are inherently expensive, time-consuming, and uncertain. Delays or failures in clinical trials could materially and adversely affect the business, financial condition, results of operations, and business prospects.

Industry Context

The biotechnology and pharmaceutical industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies often operate with substantial deficits in early stages, relying on external financing. The CDMO sector is competitive, driven by demand for specialized manufacturing and development services, and requires strict adherence to quality and regulatory standards.

Regulatory Implications

Scinai's operations, particularly its CDMO business, are subject to stringent regulatory oversight from bodies like the FDA. Failure to comply with Good Manufacturing Practices (GMP) or other regulations can lead to product recalls, fines, and reputational damage. The early-stage therapeutic pipeline also faces significant regulatory review processes for clinical trials and eventual market approval.

What Investors Should Do

1. Monitor upcoming financing rounds closely for dilution impact and terms.
2. Evaluate the progress and success of the CDMO business in generating sustainable revenue.
3. Assess the clinical development milestones and regulatory pathway for the NanoAbs pipeline.
4. Consider the risk of delisting from Nasdaq and its impact on liquidity.
5. Review the company's ability to manage cash burn and extend its operational runway.

Glossary

Going Concern Qualification

A statement by auditors indicating that there is substantial doubt about a company's ability to continue operating for the next 12 months due to financial difficulties. (This is a critical warning sign for investors, highlighting the company's precarious financial state and its reliance on future funding.)

CDMO

Contract Development and Manufacturing Organization. A company that provides services to pharmaceutical and biotechnology companies on a contract basis, from drug development to commercial manufacturing. (This is a key part of Scinai's business strategy for generating revenue, but it is subject to market demand and operational risks.)

NanoAbs

Nanobodies, which are antibody fragments derived from single-domain antibodies. They are known for their small size, stability, and potential for novel therapeutic applications. (This represents Scinai's therapeutic pipeline, which is in early stages and currently generates no revenue but holds future potential.)

Accumulated Deficit

The total cumulative net losses of a company since its inception that have not been offset by profits. (A large accumulated deficit, like Scinai's $122.0 million, indicates a long history of unprofitability and significant historical investment without commensurate returns.)

ADSs

American Depositary Shares. Certificates issued by a U.S. depositary bank representing a specified number of ordinary shares of a foreign company. (These are the securities traded on U.S. exchanges, and risks related to Nasdaq listing directly impact their liquidity and value.)

Year-Over-Year Comparison

The company has shown a slight improvement in operating losses, decreasing from $9.7 million in 2023 to $7.5 million in 2025, and negative operating cash flows have also reduced from $9.3 million to $6.0 million over the same period. However, the cash position has declined from $0.9 million in 2023 to $1.6 million in 2025, and working capital has also decreased. The accumulated deficit continues to grow, underscoring the ongoing financial challenges. No new significant risks appear to have been added, but the existing risks related to financing and operational viability remain highly relevant.

Key Financial Figures

• $1.6 m — , our cash and cash equivalents totaled $1.6 million, $1.9 million and $.9 million, re
• $1.9 million — cash equivalents totaled $1.6 million, $1.9 million and $.9 million, respectively. For the
• $7.5 m — ended, we incurred operating losses of $7.5 million, $8.6 million and $9.7 million, r
• $8.6 million — urred operating losses of $7.5 million, $8.6 million and $9.7 million, respectively, and had
• $9.7 m — osses of $7.5 million, $8.6 million and $9.7 million, respectively, and had negative c
• $6.0 m — cash flows from operating activities of $6.0 million, $6.3 million and $9.3 million, r
• $6.3 million — m operating activities of $6.0 million, $6.3 million and $9.3 million, respectively. Our cur
• $9.3 m — ities of $6.0 million, $6.3 million and $9.3 million, respectively. Our current cash p
• $122.0 m — 2024, we had an accumulated deficit of $122.0 million, $117.6 million and $122.5 millio
• $117.6 million — accumulated deficit of $122.0 million, $117.6 million and $122.5 million, respectively. Alth
• $122.5 m — t of $122.0 million, $117.6 million and $122.5 million, respectively. Although we gener
• $1.6 million — December 31, 2024, we had approximately $1.6 million and $1.9 million, respectively, in cash
• $1.9 m — , we had approximately $1.6 million and $1.9 million, respectively, in cash and cash e
• $0.46 million — short-term deposits, working capital of $0.46 million and $0.59 million, respectively, and an
• $0.59 m — s, working capital of $0.46 million and $0.59 million, respectively, and an accumulated

Filing Documents

• ea0283609-20f_scinai.htm (20-F) — 2322KB
• ea028360901ex1-1.htm (EX-1.1) — 377KB
• ea028360901ex2-3.htm (EX-2.3) — 112KB
• ea028360901ex4-16.htm (EX-4.16) — 282KB
• ea028360901ex8-1.htm (EX-8.1) — 4KB
• ea028360901ex12-1.htm (EX-12.1) — 9KB
• ea028360901ex12-2.htm (EX-12.2) — 9KB
• ea028360901ex13-1.htm (EX-13.1) — 4KB
• ea028360901ex13-2.htm (EX-13.2) — 4KB
• ea028360901ex15-1.htm (EX-15.1) — 2KB
• ea028360901_img1.jpg (GRAPHIC) — 3KB
• ea028360901_img2.jpg (GRAPHIC) — 236KB
• ea028360901_img3.jpg (GRAPHIC) — 236KB
• ea028360901_ex4-16img1.jpg (GRAPHIC) — 31KB
• ea028360901_ex4-16img2.jpg (GRAPHIC) — 32KB
• ea028360901_ex4-16img3.jpg (GRAPHIC) — 31KB
• ea028360901_ex4-16img4.jpg (GRAPHIC) — 73KB
• ea028360901_ex4-16img5.jpg (GRAPHIC) — 60KB
• ea028360901_ex4-16img6.jpg (GRAPHIC) — 106KB
• 0001213900-26-038011.txt ( ) — 11771KB
• scni-20251231.xsd (EX-101.SCH) — 70KB
• scni-20251231_cal.xml (EX-101.CAL) — 39KB
• scni-20251231_def.xml (EX-101.DEF) — 361KB
• scni-20251231_lab.xml (EX-101.LAB) — 665KB
• scni-20251231_pre.xml (EX-101.PRE) — 371KB
• ea0283609-20f_scinai_htm.xml (XML) — 1001KB

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 108 Item 12.

Description of Securities Other than Equity Securities

Description of Securities Other than Equity Securities 108 PART II Item 13. Defaults, Dividend Arrearages and Delinquencies 110 Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds 110 Item 15.

Controls and Procedures

Controls and Procedures 110 Item 16. [Reserved] 111 Item 16A. Audit Committee Financial Expert 111 Item 16B. Code of Ethics 111 Item 16C. Principal Accountant Fees and Services 111 Item 16D. Exemptions from the Listing Standards for Audit Committees 112 Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 112 Item 16F. Change in Registrant's Certifying Accountant 112 Item 16G. Corporate Governance 112 Item 16H. Mine Safety Disclosure 114 Item 16I. Disclosure Regarding Foreign Jurisdictions that prevent Inspection 114 Item 16J. Insider Trading Policies 114 Item 16K. Cybersecurity 114 PART III Item 17.

Financial Statements

Financial Statements 116 Item 18.

Financial Statements

Financial Statements 116 Item 19. Exhibits 116

Signatures

Signatures 118 Index to Consolidated Financial Statements F-1 i INTRODUCTION Certain Definitions: In this annual report, unless the context otherwise requires: references to "Scinai," the "Company," "us," "we" and "our" refer to Scinai Immunotherapeutics Ltd. (the "Registrant"), an Israeli company; references to "ordinary shares," "our shares" and similar expressions refer to the Registrant's ordinary shares, no par value; references to "ADS" refer to the Registrant's American Depositary Shares references to "Company product candidate(s)" refer to any future, newly licensed or acquired product candidate(s); references to "CDMO business unit" refer to the Registrant's contract development and manufacturing services business unit. references to "R&D business unit" refer to the Registrant's research and development business unit focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked, pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs. references to "dollars," "U.S. dollars" and "

forward-looking statements by terminology such as "believe," "may," "estimate," "continue,"

forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions, but these are not the only ways these statements are identified. Forward-looking statements are based on information we have when those statements are made or our management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Unless we are required to do so under U.S. federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements. Some of the factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statements contained herein, include but are not limited to: our history of operating losses, our lack of current profitability and our ability to achieve and sustain profitability, including our ability to generate sufficient revenues from our CDMO activities to support our operations; our need to obtain additional financing to fund our operations and development programs, the timing and availability of such financing, and the potential dilution to our existing shareholders or restrictions imposed by debt financing; our ability to maintain compliance with the continued listing requirements of Nasdaq; the success of our business strategy, including our ability to develop and grow our CDMO business while advancing our therapeutic development programs; our ability to generate demand for our CDMO services, to attract and retain customers, to enter into and execute contracts on commercially acceptable terms, and to deliver such services in accordance with required quality standards and timelines; risks associated with the integrat

Risk Factors

Risk Factors An investment in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the factors described below, together with all other information included in this annual report, including our financial statements and the related notes included elsewhere in this annual report. Our business includes both therapeutic development activities and a contract development and manufacturing organization (CDMO) business, each of which is subject to distinct risks and uncertainties. We may face additional risks and uncertainties not currently known to us or that we currently deem to be immaterial. If any of these risks occur, our business, financial condition, results of operations and business prospects could be materially and adversely affected. In that event, the trading price of the ADSs could decline and you could lose all or part of your investment. Summary of Risk Factors The following is a summary of some of the principal risks we face. The list below is not exhaustive, and investors should read this "Risk factors" section in full. We have a going concern qualification and will require substantial additional financing to fund our operations and development programs. If we are unable to obtain additional capital when needed, we may be required to delay, limit, reduce or terminate our activities, or cease operations. Any such financing may also result in significant dilution to our existing shareholders or impose restrictive covenants. We have a history of operating losses and are not currently profitable. Although we generate revenues from our CDMO activities, we may continue to incur losses and may not achieve profitability in the near future, or at all. Our failure to meet the continued listing requirements of Nasdaq could result in the delisting of our ADSs, which could adversely affect the market liquidity and price of our shares. Our business strategy, including the development and growth of

View Full Filing

View this 20-F filing on SEC EDGAR